Develops novel therapies for rare metabolic diseases using a precision medicine approach to address unmet medical needs.
Applied Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company dedicated to pioneering new treatments for cardiovascular disease, galactosemia, and diabetic complications. Founded in 2016 and based in New York, New York, Applied Therapeutics focuses on developing novel therapies that address critical medical needs. The company's lead product candidate, AT-007, has progressed through phase 1/2 trials for galactosemia treatment in both healthy volunteers and adults, with ongoing pediatric studies aimed at younger patients affected by this metabolic disorder.
In addition to AT-007, Applied Therapeutics is advanccing AT-001 through phase III clinical trials. AT-001 targets diabetic cardiomyopathy and diabetic peripheral neuropathy, aiming to address significant complications of diabetes. The company's pipeline includes AT-003, currently in preclinical stages for the treatment of diabetic retinopathy, and AT-104, a PI3K inhibitor developed for orphan hematological oncology specifically targeting T Cell Acute Lymphoblastic Leukemia.
Applied Therapeutics combines cutting-edge research with a commitment to clinical advancement, positioning itself at the forefront of therapeutic innovation. With a robust portfolio addressing diverse medical conditions, the company continues to push the boundaries of biopharmaceutical development to improve outcomes for patients worldwide.